Interestingly, pharmacological PPAR-α agonist treatment using fenofibrate reverted hepatic steatosis, but only partially improved inflammation in MCD-fed ATGL knockout mice indicating a PPAR-α independent protective effect of ATGL on hepatic inflammation [141]. Here, PNPLA2 is linked to fatty liver disease.